Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: Longitudinal results of HVTN 906

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 2, 2013, Pages 239-244

  Koblin, Beryl A ^a   Metch, Barbara ^b   Novak, Richard M ^c   Morgan, Cecilia ^b   Lucy, Debbie ^a   Dunbar, Debora ^d   Graham, Parrie ^c   Swann, Edith ^e   Madenwald, Tamra ^b   Escamilia, Gina ^b   Frank, Ian ^d  

^a NEW YORK BLOOD CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Heterosexual transmission; HIV vaccine trials; US women

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; COHORT ANALYSIS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HIGH RISK BEHAVIOR; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREGNANCY; PREGNANCY TEST; PRIORITY JOURNAL; RISK ASSESSMENT; SEXUALITY; UNITED STATES; UNPROTECTED SEX; CLINICAL TRIAL (TOPIC); MULTICENTER STUDY; PATIENT SELECTION; QUESTIONNAIRE; UNSAFE SEX;

ADULT; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; FEASIBILITY STUDIES; FEMALE; HIV INFECTIONS; HUMANS; PATIENT SELECTION; PREGNANCY; QUESTIONNAIRES; RISK-TAKING; SEXUAL PARTNERS; UNITED STATES; UNSAFE SEX; YOUNG ADULT;

MLCS; MLOWN;

EID: 84879776911     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828ded1a     Document Type: Article

References (27)

1. Djomand G, Metch B, Zorrilla CD, et al. The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2008;48:82-89.
2. Koblin BA, Taylor PE, Avrett S, et al. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: project ACHIEVE. AIDS community health initiative enroute to the vaccine effort. AIDS. 1996;10:1555-1561.
3. Centers for Disease Control and Prevention. HIV surveillance-epidemiology of HIV infection (through 2010). Available at: http://www.cdc.gov/hiv/topics/ surveillance/resources/slides/general/index.html. Accessed August 8, 2012.
4. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001; 344:720-725.
5. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347: 1652-1661.
6. Gandhi M, Bacchetti P, Miotti P, et al. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002;35:313-322.
7. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012.
8. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
9. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
10. CDC. HIV in the United States. Available at: www.cdc.gov. Accessed June 14, 2011.
11. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? the HIVNET Vaccine Preparedness Study. Am J Epidemiol. 2001;153:619-627.
12. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654-665.
13. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881-1893.
14. Adimora AA, Schoenbach VJ, Doherty IA. Concurrent sexual partnerships among men in the United States. Am J Public Health. 2007;97: 2230-2237.
15. Adimora AA, Schoenbach VJ, Floris-Moore MA. Ending the epidemic of heterosexual HIV transmission among African Americans. Am J Prev Med. 2009;37:468-471.
16. Grinstead OA, Faigeles B, Comfort M, et al. HIV, STD, and hepatitis risk to primary female partners of men being released from prison. Women Health. 2005;41:63-80.
17. CDC. Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence-24 cities, United States, 2006-2007. MMWR Morb Mortal Wkly Rep. 2011;60:1045-1049.
18. Metch B, Frank I, Novak R, et al. Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials. AIDS Behav. 2013;17:760-772.
19. HIVNET D01: Vaccine preparedness study/uninfected protocol cohort. Available at: http://www.hptn.org/network-information/Public-Data- Sets/VPS-UPCdataFiles/VPS-UPC.pdf. Accessed February 4, 2013.
20. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6:e17502.
21. Hodder SL, Justman J, Hughes JP, et al. HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med. 2013;158:10-18.
22. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
23. Cunningham JA. Regression to the mean: what does it mean? Alcohol Alcohol. 2006;41:580.
24. Jenness SM, Neaigus A, Murrill CS, et al. Estimated HIV incidence among high-risk heterosexuals in New York City, 2007. J Acquir Immune Defic Syndr. 2011;56:193-197.
25. Ventura SJ, Curtin SC, Abma JC, et al. National vital statistics reports. Estimated Pregnancy Rates and Rates of Pregnancy Outcomes for the United States, 1990-2008. Vol. 60, no 7. Hyattsville, MD: National Center for Health Statistics; 2012.
26. Brown-Peterside P, Ren L, Hirsch A, et al. Pregnancies among high-risk women in the first ever HIV vaccine efficacy trial. AIDS. 2003;17: 787-788.
27. Latka MH, Fielding K, Gray GE, et al. Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women. PLoS One. 2012;7:e31387.